Search
for
Sort by
Research
420-450 / 1000+ resultsresearch Targeting Solid Tumours With Potassium Channel Activators. A Return to Fundamentals?
Potassium channel activators like nicotinamide and minoxidil might help treat solid tumors.
research The therapeutic potential of CRTH2/DP2 beyond allergy and asthma
CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.
research Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
research 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
Upadacitinib effectively treats pyoderma gangrenosum.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research CSF 5-HIAA as a predictor of treatment response in trichotillomania.
Higher CSF 5-HIAA levels may predict better response to serotonin re-uptake inhibitors in trichotillomania.
research 14. 膠原病患者における心理状態の統計学的観察(第45回 日本心身医学会東北地方会 演題抄録)
Suppressing ODC activity reduces tumor growth in hair follicles.
research Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study
Using 2.5 mg/mL triamcinolone acetonide is effective for hair growth in alopecia areata with fewer side effects.
research Serial Hydrolysis for the Simultaneous Analysis of Catecholamines and Steroids in the Urine of Patients with Alopecia Areata
A new method was created to analyze certain chemicals in the urine of alopecia areata patients, revealing they have higher metanephrine content. This method can also be used for other related diseases.
research A COMPARISON OF INTRA-LESIONAL TRIAMINOLONE HEXA-CETONIDE AND TRIAMCINOLONE ACETONIDE IN ALOPECIA AREATA
Both steroids effectively promote hair growth for at least 9 months.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research MachineLearning-Driven Optimization of TherapeuticSubstance Composition for High-Hardness, Fast-Dissolving Microneedlesfor Androgenetic Alopecia Treatment
Machine learning optimized microneedles promote hair regrowth better than minoxidil without safety risks.
research ODP056 The Treatment of Opioid Addiction Leading to Secondary Adrenal Insufficiency
Long-term treatment with buprenorphine/naloxone for opioid addiction may lead to secondary adrenal insufficiency.
research Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
research Comparison of Intra-lesional Methotrexate and Intra-lesional Triamcinolone Acteonid in the treatment of Localized Alopecia Areata
Both treatments for localized alopecia areata are equally effective.
research Thyrotropin releasing hormone (TRH): a new player in human hair‐growth control
TRH stimulates human hair growth and extends the hair growth phase.
research Potassium channel openers: pharmacological and clinical aspects
Potassium channel openers could help treat cardiovascular diseases and asthma but require better targeting to specific tissues for effective use.
research Polymer conjugated retinoids for controlled transdermal delivery
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
research Parathyroid hormone-related peptide and the hair cycle - is it the agonists or the antagonists that cause hair growth?
PTHRP agonists can stimulate hair growth, especially in damaged follicles, while antagonists may initially increase growth but ultimately inhibit it.
research Mesotherapy with dutasteride in the treatment of androgenetic alopecia
research Potassium channel openers: therapeutic potential in cardiology and medicine
Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
research Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
Patients on dabrafenib and trametinib for melanoma often experience skin side effects.
research Drug news and therapeutic news
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
research Clascoterone as a novel treatment for androgenetic alopecia
Clascoterone may be a promising treatment for hair loss.
research Extracellular ATP and Adenosine Signaling in Arabidopsis: Investigating Cellular Modulation
Extracellular ATP promotes growth, while adenosine inhibits it in Arabidopsis plants.
research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.